Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial

The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study w...

Full description

Saved in:
Bibliographic Details
Published inEuropean heart journal Vol. 37; no. 38; pp. 2858 - 2865
Main Authors Kuck, Karl-Heinz, Fürnkranz, Alexander, Chun, K.R. Julian, Metzner, Andreas, Ouyang, Feifan, Schlüter, Michael, Elvan, Arif, Lim, Hae W., Kueffer, Fred J., Arentz, Thomas, Albenque, Jean-Paul, Tondo, Claudio, Kühne, Michael, Sticherling, Christian, Brugada, Josep
Format Journal Article
LanguageEnglish
Published England Oxford University Press 07.10.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study was to assess outcome parameters that are important for the daily clinical management of patients using key secondary analyses. Specifically, reinterventions, rehospitalizations, and quality-of-life were examined in this randomized trial of cryoballoon vs. RFC catheter ablation. Patients (374 subjects in the cryoballoon group and 376 subjects in the RFC group) were evaluated in the modified intention-to-treat cohort. After the index ablation, log-rank testing over 1000 days of follow-up demonstrated that there were statistically significant differences in favour of cryoballoon ablation with respect to repeat ablations (11.8% cryoballoon vs. 17.6% RFC; P = 0.03), direct-current cardioversions (3.2% cryoballoon vs. 6.4% RFC; P = 0.04), all-cause rehospitalizations (32.6% cryoballoon vs. 41.5% RFC; P = 0.01), and cardiovascular rehospitalizations (23.8% cryoballoon vs. 35.9% RFC; P < 0.01). There were no statistical differences between groups in the quality-of-life surveys (both mental and physical) as measured by the Short Form-12 health survey and the EuroQol five-dimension questionnaire. There was an improvement in both mental and physical quality-of-life in all patients that began at 6 months after the index ablation and was maintained throughout the 30 months of follow-up. Patients treated with cryoballoon as opposed to RFC ablation had significantly fewer repeat ablations, direct-current cardioversions, all-cause rehospitalizations, and cardiovascular rehospitalizations during follow-up. Both patient groups improved in quality-of-life scores after AF ablation. ClinicalTrials.gov identifier: NCT01490814.
AbstractList The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study was to assess outcome parameters that are important for the daily clinical management of patients using key secondary analyses. Specifically, reinterventions, rehospitalizations, and quality-of-life were examined in this randomized trial of cryoballoon vs. RFC catheter ablation. Patients (374 subjects in the cryoballoon group and 376 subjects in the RFC group) were evaluated in the modified intention-to-treat cohort. After the index ablation, log-rank testing over 1000 days of follow-up demonstrated that there were statistically significant differences in favour of cryoballoon ablation with respect to repeat ablations (11.8% cryoballoon vs. 17.6% RFC; P = 0.03), direct-current cardioversions (3.2% cryoballoon vs. 6.4% RFC; P = 0.04), all-cause rehospitalizations (32.6% cryoballoon vs. 41.5% RFC; P = 0.01), and cardiovascular rehospitalizations (23.8% cryoballoon vs. 35.9% RFC; P < 0.01). There were no statistical differences between groups in the quality-of-life surveys (both mental and physical) as measured by the Short Form-12 health survey and the EuroQol five-dimension questionnaire. There was an improvement in both mental and physical quality-of-life in all patients that began at 6 months after the index ablation and was maintained throughout the 30 months of follow-up. Patients treated with cryoballoon as opposed to RFC ablation had significantly fewer repeat ablations, direct-current cardioversions, all-cause rehospitalizations, and cardiovascular rehospitalizations during follow-up. Both patient groups improved in quality-of-life scores after AF ablation. ClinicalTrials.gov identifier: NCT01490814.
The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study was to assess outcome parameters that are important for the daily clinical management of patients using key secondary analyses. Specifically, reinterventions, rehospitalizations, and quality-of-life were examined in this randomized trial of cryoballoon vs. RFC catheter ablation.AIMSThe primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study was to assess outcome parameters that are important for the daily clinical management of patients using key secondary analyses. Specifically, reinterventions, rehospitalizations, and quality-of-life were examined in this randomized trial of cryoballoon vs. RFC catheter ablation.Patients (374 subjects in the cryoballoon group and 376 subjects in the RFC group) were evaluated in the modified intention-to-treat cohort. After the index ablation, log-rank testing over 1000 days of follow-up demonstrated that there were statistically significant differences in favour of cryoballoon ablation with respect to repeat ablations (11.8% cryoballoon vs. 17.6% RFC; P = 0.03), direct-current cardioversions (3.2% cryoballoon vs. 6.4% RFC; P = 0.04), all-cause rehospitalizations (32.6% cryoballoon vs. 41.5% RFC; P = 0.01), and cardiovascular rehospitalizations (23.8% cryoballoon vs. 35.9% RFC; P < 0.01). There were no statistical differences between groups in the quality-of-life surveys (both mental and physical) as measured by the Short Form-12 health survey and the EuroQol five-dimension questionnaire. There was an improvement in both mental and physical quality-of-life in all patients that began at 6 months after the index ablation and was maintained throughout the 30 months of follow-up.METHODS AND RESULTSPatients (374 subjects in the cryoballoon group and 376 subjects in the RFC group) were evaluated in the modified intention-to-treat cohort. After the index ablation, log-rank testing over 1000 days of follow-up demonstrated that there were statistically significant differences in favour of cryoballoon ablation with respect to repeat ablations (11.8% cryoballoon vs. 17.6% RFC; P = 0.03), direct-current cardioversions (3.2% cryoballoon vs. 6.4% RFC; P = 0.04), all-cause rehospitalizations (32.6% cryoballoon vs. 41.5% RFC; P = 0.01), and cardiovascular rehospitalizations (23.8% cryoballoon vs. 35.9% RFC; P < 0.01). There were no statistical differences between groups in the quality-of-life surveys (both mental and physical) as measured by the Short Form-12 health survey and the EuroQol five-dimension questionnaire. There was an improvement in both mental and physical quality-of-life in all patients that began at 6 months after the index ablation and was maintained throughout the 30 months of follow-up.Patients treated with cryoballoon as opposed to RFC ablation had significantly fewer repeat ablations, direct-current cardioversions, all-cause rehospitalizations, and cardiovascular rehospitalizations during follow-up. Both patient groups improved in quality-of-life scores after AF ablation.CONCLUSIONPatients treated with cryoballoon as opposed to RFC ablation had significantly fewer repeat ablations, direct-current cardioversions, all-cause rehospitalizations, and cardiovascular rehospitalizations during follow-up. Both patient groups improved in quality-of-life scores after AF ablation.ClinicalTrials.gov identifier: NCT01490814.CLINICAL TRIAL REGISTRATIONClinicalTrials.gov identifier: NCT01490814.
AIMS: The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency current (RFC) catheter ablation in patients with drug-refractory symptomatic paroxysmal atrial fibrillation (AF). The aim of the current study was to assess outcome parameters that are important for the daily clinical management of patients using key secondary analyses. Specifically, reinterventions, rehospitalizations, and quality-of-life were examined in this randomized trial of cryoballoon vs. RFC catheter ablation. METHODS AND RESULTS: Patients (374 subjects in the cryoballoon group and 376 subjects in the RFC group) were evaluated in the modified intention-to-treat cohort. After the index ablation, log-rank testing over 1000 days of follow-up demonstrated that there were statistically significant differences in favour of cryoballoon ablation with respect to repeat ablations (11.8% cryoballoon vs. 17.6% RFC; P = 0.03), direct-current cardioversions (3.2% cryoballoon vs. 6.4% RFC; P = 0.04), all-cause rehospitalizations (32.6% cryoballoon vs. 41.5% RFC; P = 0.01), and cardiovascular rehospitalizations (23.8% cryoballoon vs. 35.9% RFC; P < 0.01). There were no statistical differences between groups in the quality-of-life surveys (both mental and physical) as measured by the Short Form-12 health survey and the EuroQol five-dimension questionnaire. There was an improvement in both mental and physical quality-of-life in all patients that began at 6 months after the index ablation and was maintained throughout the 30 months of follow-up. CONCLUSION: Patients treated with cryoballoon as opposed to RFC ablation had significantly fewer repeat ablations, direct-current cardioversions, all-cause rehospitalizations, and cardiovascular rehospitalizations during follow-up. Both patient groups improved in quality-of-life scores after AF ablation
Author Fürnkranz, Alexander
Metzner, Andreas
Tondo, Claudio
Lim, Hae W.
Schlüter, Michael
Albenque, Jean-Paul
Sticherling, Christian
Chun, K.R. Julian
Kueffer, Fred J.
Arentz, Thomas
Kühne, Michael
Kuck, Karl-Heinz
Brugada, Josep
Ouyang, Feifan
Elvan, Arif
AuthorAffiliation 1 Department of Cardiology, Asklepios Klinik St. Georg, Lohmühlenstr. 5, 20099 Hamburg, Germany
3 Isala Klinieken, Zwolle, The Netherlands
8 Universitätsspital Basel, Basel, Switzerland
5 Herz-Zentrum, Bad Krozingen, Germany
4 Medtronic, Inc., Minneapolis, MN, USA
6 Clinique Pasteur, Toulouse, France
7 Centro Cardiologico Monzino, University of Milan, Milan, Italy
2 Cardioangiologisches Centrum Bethanien, Frankfurt, Germany
9 Hospital Clinic, University of Barcelona, Barcelona, Spain
AuthorAffiliation_xml – name: 9 Hospital Clinic, University of Barcelona, Barcelona, Spain
– name: 4 Medtronic, Inc., Minneapolis, MN, USA
– name: 2 Cardioangiologisches Centrum Bethanien, Frankfurt, Germany
– name: 6 Clinique Pasteur, Toulouse, France
– name: 8 Universitätsspital Basel, Basel, Switzerland
– name: 5 Herz-Zentrum, Bad Krozingen, Germany
– name: 7 Centro Cardiologico Monzino, University of Milan, Milan, Italy
– name: 1 Department of Cardiology, Asklepios Klinik St. Georg, Lohmühlenstr. 5, 20099 Hamburg, Germany
– name: 3 Isala Klinieken, Zwolle, The Netherlands
Author_xml – sequence: 1
  givenname: Karl-Heinz
  surname: Kuck
  fullname: Kuck, Karl-Heinz
– sequence: 2
  givenname: Alexander
  surname: Fürnkranz
  fullname: Fürnkranz, Alexander
– sequence: 3
  givenname: K.R. Julian
  surname: Chun
  fullname: Chun, K.R. Julian
– sequence: 4
  givenname: Andreas
  surname: Metzner
  fullname: Metzner, Andreas
– sequence: 5
  givenname: Feifan
  surname: Ouyang
  fullname: Ouyang, Feifan
– sequence: 6
  givenname: Michael
  surname: Schlüter
  fullname: Schlüter, Michael
– sequence: 7
  givenname: Arif
  surname: Elvan
  fullname: Elvan, Arif
– sequence: 8
  givenname: Hae W.
  surname: Lim
  fullname: Lim, Hae W.
– sequence: 9
  givenname: Fred J.
  surname: Kueffer
  fullname: Kueffer, Fred J.
– sequence: 10
  givenname: Thomas
  surname: Arentz
  fullname: Arentz, Thomas
– sequence: 11
  givenname: Jean-Paul
  surname: Albenque
  fullname: Albenque, Jean-Paul
– sequence: 12
  givenname: Claudio
  surname: Tondo
  fullname: Tondo, Claudio
– sequence: 13
  givenname: Michael
  surname: Kühne
  fullname: Kühne, Michael
– sequence: 14
  givenname: Christian
  surname: Sticherling
  fullname: Sticherling, Christian
– sequence: 15
  givenname: Josep
  surname: Brugada
  fullname: Brugada, Josep
BackLink https://www.ncbi.nlm.nih.gov/pubmed/27381589$$D View this record in MEDLINE/PubMed
BookMark eNp1Uk1v1DAQtVAR3RbunJCPHBpqO7HjcECqli2sVIGEQOJmOd4x6yqJt7ZTmv4qfiLe7nYFSBys0Xy898Yzc4KOBj8AQi8peUNJU57DGNagQ7o-h_VPJvkTNKOcsaIRFT9CM0IbXgghvx-jkxivCSFSUPEMHbO6lJTLZoZ-zcPkW9113g_YBxz0ynkb4GaEwUxYt51OLqdszsWp3yTf54DBGx383RR73WGdgsvGuja4blf-FgdwQ4JwC8PWP8v-2seNS7pz93oX0sMK34w5kKbC26JzFrAfk_E9ROwGnNaAL5dfFvji03u8nC_wg85z9NTqLsKLvT1F3y4XX-cfi6vPH5bzi6vCcFKlompZw0pdyaaxLTGiFg2tG1sCBanLWlhJqlVJRMtabiWlWpKWc1nZsjGgoSxP0bsd72Zse1iZ_JGgO7UJrtdhUl479XdmcGv1w98qTmpSVTIT0B2BiaNRAQwEo9MD8OBsHyM1UyVhRJKMeb0XDT5vICbVu2ggT3UAP0ZFJRM1pbziufTVn_0dGntcbS4Qe_3gYwxglcnj344-t-s6RYna3pA63JDa3VAGkn-Aj9z_hfwGAYbUFQ
CitedBy_id crossref_primary_10_1186_s12872_022_03015_8
crossref_primary_10_1002_clc_24092
crossref_primary_10_1093_eurheartj_ehw458
crossref_primary_10_1111_jce_13936
crossref_primary_10_1136_openhrt_2018_000949
crossref_primary_10_1093_europace_euad374
crossref_primary_10_1111_jce_15317
crossref_primary_10_1155_2018_3629384
crossref_primary_10_1016_j_ahj_2019_12_006
crossref_primary_10_1093_europace_euae103
crossref_primary_10_4070_kcj_2024_0044
crossref_primary_10_1038_s41591_024_03114_3
crossref_primary_10_17925_EJAE_2022_8_1_13
crossref_primary_10_17802_2306_1278_2018_7_2_137_145
crossref_primary_10_1007_s00380_021_01963_3
crossref_primary_10_1016_j_hrthm_2017_05_029
crossref_primary_10_1016_j_ijcard_2017_06_046
crossref_primary_10_1093_eurheartj_ehw344
crossref_primary_10_1007_s10840_020_00725_x
crossref_primary_10_1111_jce_15308
crossref_primary_10_1007_s10840_017_0277_z
crossref_primary_10_1111_jce_14459
crossref_primary_10_1253_circj_CJ_21_0094
crossref_primary_10_1136_bmj_n379
crossref_primary_10_1007_s00059_017_4567_0
crossref_primary_10_1136_heartjnl_2018_313057
crossref_primary_10_1016_j_hrthm_2017_10_038
crossref_primary_10_3390_jcm11195862
crossref_primary_10_1016_j_ijcard_2019_02_054
crossref_primary_10_1111_pace_13810
crossref_primary_10_2459_JCM_0000000000000688
crossref_primary_10_1253_circj_CJ_20_0255
crossref_primary_10_1016_j_ijcha_2020_100576
crossref_primary_10_1016_j_jacc_2020_02_025
crossref_primary_10_1093_eurheartj_ehw674
crossref_primary_10_1016_j_hjc_2023_03_008
crossref_primary_10_1016_j_joa_2017_08_001
crossref_primary_10_1136_openhrt_2021_001718
crossref_primary_10_1093_ehjopen_oeae065
crossref_primary_10_1253_circrep_CR_19_0125
crossref_primary_10_1007_s10840_022_01321_x
crossref_primary_10_17925_EJAE_2018_4_2_56
crossref_primary_10_1253_circj_CJ_18_1035
crossref_primary_10_3390_jcdd11120385
crossref_primary_10_3904_kjm_2022_97_1_5
crossref_primary_10_1111_jcpt_12671
crossref_primary_10_1111_pace_14341
crossref_primary_10_1093_europace_euaa406
crossref_primary_10_1055_a_1811_8195
crossref_primary_10_1016_j_cjca_2019_05_024
crossref_primary_10_1016_j_jacep_2020_08_041
crossref_primary_10_18501_arrhythmia_2018_012
crossref_primary_10_1038_s41598_025_90920_5
crossref_primary_10_1111_jce_15446
crossref_primary_10_1016_j_recesp_2020_10_022
crossref_primary_10_1253_circj_CJ_19_0151
crossref_primary_10_1007_s10840_022_01388_6
crossref_primary_10_1016_j_ahj_2019_04_015
crossref_primary_10_1007_s11936_020_00840_y
crossref_primary_10_1186_s13019_024_03332_3
crossref_primary_10_1093_eurheartj_ehae373
crossref_primary_10_1161_CIRCEP_121_010040
crossref_primary_10_3390_jcm11051166
crossref_primary_10_1024_1661_8157_a002725
crossref_primary_10_1016_j_ijcard_2019_10_053
crossref_primary_10_1007_s10840_020_00748_4
crossref_primary_10_1016_j_cpcardiol_2022_101383
crossref_primary_10_5604_01_3001_0010_7497
crossref_primary_10_1007_s10840_023_01718_2
crossref_primary_10_1161_CIR_0000000000001193
crossref_primary_10_1016_j_jacep_2022_04_011
crossref_primary_10_1007_s10840_021_01035_6
crossref_primary_10_3390_jcdd9030088
crossref_primary_10_1007_s00392_019_01580_1
crossref_primary_10_2217_fca_2020_0066
crossref_primary_10_1111_jce_16561
crossref_primary_10_1002_joa3_12780
crossref_primary_10_1007_s10840_024_01771_5
crossref_primary_10_15420_usc_2017_28_3
crossref_primary_10_1007_s10840_019_00564_5
crossref_primary_10_1007_s10840_019_00601_3
crossref_primary_10_1007_s10840_019_00542_x
crossref_primary_10_1007_s10840_019_00588_x
crossref_primary_10_36516_jocass_1124247
crossref_primary_10_31083_j_rcm2502071
crossref_primary_10_1007_s10840_022_01349_z
crossref_primary_10_17802_2306_1278_2018_7_4S_6_14
crossref_primary_10_1007_s10840_020_00893_w
crossref_primary_10_1016_j_jacep_2018_11_006
crossref_primary_10_1093_europace_euz142
crossref_primary_10_1371_journal_pone_0270642
crossref_primary_10_1007_s10840_022_01195_z
crossref_primary_10_2174_0929867324666170918122502
crossref_primary_10_1007_s00380_019_01386_1
crossref_primary_10_1111_chd_12859
crossref_primary_10_29328_journal_jccm_1001090
crossref_primary_10_1093_europace_euab281
crossref_primary_10_1093_europace_euac131
crossref_primary_10_11613_BM_2019_020902
crossref_primary_10_1371_journal_pone_0259999
crossref_primary_10_1016_j_ijcard_2018_10_097
crossref_primary_10_1093_europace_euad106
crossref_primary_10_1016_j_ijcard_2018_07_051
crossref_primary_10_1136_openhrt_2023_002423
crossref_primary_10_1007_s10840_025_01982_4
crossref_primary_10_1007_s00399_021_00836_6
crossref_primary_10_1016_j_jjcc_2019_01_004
crossref_primary_10_1093_europace_euz155
crossref_primary_10_1253_circj_CJ_16_1334
crossref_primary_10_1007_s11845_021_02560_z
crossref_primary_10_1016_j_hrthm_2024_03_017
crossref_primary_10_1038_s41598_021_96820_8
crossref_primary_10_1111_jce_16220
crossref_primary_10_1186_s13063_024_07971_8
crossref_primary_10_36660_abc_20190307
crossref_primary_10_1161_CIRCRESAHA_120_316402
crossref_primary_10_1007_s10840_023_01494_z
crossref_primary_10_1016_j_jjcc_2019_02_006
crossref_primary_10_1007_s10840_019_00591_2
crossref_primary_10_17816_clinpract8178_82
crossref_primary_10_1007_s10840_020_00927_3
crossref_primary_10_1080_17434440_2017_1358086
crossref_primary_10_1016_j_tcm_2016_12_002
crossref_primary_10_1007_s12325_023_02765_x
crossref_primary_10_1186_s40359_023_01457_z
crossref_primary_10_1161_JAHA_117_006043
crossref_primary_10_1080_20479700_2023_2290341
crossref_primary_10_1007_s00399_022_00843_1
crossref_primary_10_1016_j_hrthm_2017_05_003
crossref_primary_10_1007_s00392_020_01751_5
crossref_primary_10_1111_jce_15246
crossref_primary_10_35336_VA_2022_4_07
crossref_primary_10_1111_jce_16337
crossref_primary_10_1186_s12872_017_0566_6
crossref_primary_10_1186_s43044_024_00518_x
crossref_primary_10_1007_s12181_017_0146_0
crossref_primary_10_4264_numa_77_1_7
crossref_primary_10_1093_europace_euae095
crossref_primary_10_1002_joa3_13082
crossref_primary_10_1016_j_jacc_2017_06_039
crossref_primary_10_1007_s10840_022_01132_0
crossref_primary_10_1111_jce_15009
crossref_primary_10_1007_s10840_021_01052_5
crossref_primary_10_1093_europace_euaa055
crossref_primary_10_1371_journal_pone_0206362
crossref_primary_10_1093_europace_euad329
crossref_primary_10_31083_j_rcm2504140
crossref_primary_10_1016_j_vhri_2019_05_004
crossref_primary_10_1016_j_hlc_2019_07_020
crossref_primary_10_1093_europace_euab029
crossref_primary_10_1016_j_hrthm_2017_05_012
crossref_primary_10_1111_jce_14271
crossref_primary_10_1007_s00380_021_01785_3
crossref_primary_10_1016_j_jacep_2020_04_017
crossref_primary_10_1097_MS9_0000000000002858
crossref_primary_10_17116_Cardiobulletin20221701152
crossref_primary_10_1007_s10840_018_0335_1
crossref_primary_10_4103_IJHR_IJHR_6_17
crossref_primary_10_1111_jce_14741
crossref_primary_10_1093_europace_eux274
crossref_primary_10_1161_CIRCULATIONAHA_119_042622
crossref_primary_10_15420_ecr_2019_8_1
crossref_primary_10_15836_ccar2017_240
crossref_primary_10_1093_europace_eux275
crossref_primary_10_1253_circj_CJ_19_0766
crossref_primary_10_1115_1_4047134
crossref_primary_10_1161_JAHA_118_010777
crossref_primary_10_3389_fcvm_2021_664647
crossref_primary_10_1097_JCN_0000000000000646
crossref_primary_10_1002_clc_23951
crossref_primary_10_1111_pace_13077
crossref_primary_10_3390_diagnostics12061322
crossref_primary_10_1007_s00399_023_00972_1
crossref_primary_10_1111_jce_14972
crossref_primary_10_1016_j_clinthera_2018_11_008
crossref_primary_10_1111_jce_13648
crossref_primary_10_17116_Cardiobulletin20181303110
crossref_primary_10_24060_2076_3093_2018_8_4_303_309
crossref_primary_10_36660_abc_20200204
crossref_primary_10_1016_j_jval_2019_02_001
crossref_primary_10_1016_j_jacep_2018_12_004
crossref_primary_10_1093_eurheartj_ehw629
crossref_primary_10_1016_j_cjca_2024_07_021
crossref_primary_10_3389_fcvm_2022_853149
crossref_primary_10_1161_JAHA_120_020506
crossref_primary_10_1016_j_jacep_2018_07_007
crossref_primary_10_1007_s10840_023_01680_z
crossref_primary_10_1111_jce_15383
crossref_primary_10_3390_jcm11247400
crossref_primary_10_1007_s10840_022_01411_w
crossref_primary_10_1016_j_ipej_2020_09_003
crossref_primary_10_1093_europace_eux050
crossref_primary_10_1007_s00380_019_01471_5
crossref_primary_10_2139_ssrn_4151282
crossref_primary_10_1093_europace_euae043
crossref_primary_10_1097_RTI_0000000000000441
crossref_primary_10_1053_j_jvca_2020_03_002
crossref_primary_10_1016_j_cjca_2025_02_033
crossref_primary_10_1038_nrcardio_2016_141
crossref_primary_10_1093_eurheartj_suab089
crossref_primary_10_1007_s10840_018_0483_3
crossref_primary_10_3390_biomedicines10020450
crossref_primary_10_1093_eurheartj_ehaa612
crossref_primary_10_15420_aer_2021_46
crossref_primary_10_1016_j_repce_2019_05_026
crossref_primary_10_1093_europace_eux066
crossref_primary_10_1093_europace_euaa132
crossref_primary_10_1161_CIRCEP_118_006989
crossref_primary_10_3390_jcdd10020055
crossref_primary_10_1016_j_amjms_2019_06_004
crossref_primary_10_1007_s12170_021_00668_6
crossref_primary_10_1042_BSR20193128
crossref_primary_10_1080_14779072_2021_1941875
crossref_primary_10_1016_j_hrthm_2018_04_021
crossref_primary_10_1016_j_ijcard_2024_132557
crossref_primary_10_1016_j_repc_2019_05_013
crossref_primary_10_18663_tjcl_1526770
crossref_primary_10_3390_jcm12247556
crossref_primary_10_1016_j_ijcha_2023_101244
crossref_primary_10_4070_kcj_2019_0226
crossref_primary_10_1002_clc_22782
crossref_primary_10_1093_europace_euab318
crossref_primary_10_17116_hirurgia202106226
crossref_primary_10_1161_JAHA_117_007559
crossref_primary_10_3390_biomedicines11071825
crossref_primary_10_1161_CIRCEP_119_007247
crossref_primary_10_1080_17434440_2019_1653181
crossref_primary_10_1016_j_ijcha_2021_100847
crossref_primary_10_1093_europace_euac094
crossref_primary_10_1097_HCO_0000000000000942
crossref_primary_10_1111_jce_13209
crossref_primary_10_1007_s00059_017_4565_2
crossref_primary_10_1093_europace_euy208
crossref_primary_10_1016_j_hjc_2024_05_011
crossref_primary_10_1016_j_hrthm_2016_12_007
crossref_primary_10_1111_pace_14130
crossref_primary_10_1002_clc_22653
crossref_primary_10_1253_circj_CJ_21_0608
crossref_primary_10_1007_s12265_018_9844_7
crossref_primary_10_1161_CIRCEP_118_006204
crossref_primary_10_1111_pace_13975
crossref_primary_10_1111_pace_14943
crossref_primary_10_1007_s10840_019_00694_w
crossref_primary_10_1007_s10840_023_01645_2
crossref_primary_10_1111_pace_13858
crossref_primary_10_1097_HCO_0000000000000932
crossref_primary_10_1111_pace_14709
crossref_primary_10_1016_j_hrcr_2019_02_008
crossref_primary_10_1093_europace_euz313
crossref_primary_10_4264_numa_78_1_21
crossref_primary_10_1016_j_jacc_2023_08_017
crossref_primary_10_1016_j_joa_2017_07_001
crossref_primary_10_18087_cardio_2022_6_n1667
crossref_primary_10_1136_heartjnl_2021_319382
crossref_primary_10_1093_europace_euz309
crossref_primary_10_1016_j_jccase_2021_05_007
crossref_primary_10_1111_pace_14149
crossref_primary_10_1111_jce_13103
crossref_primary_10_1186_s12933_024_02388_8
crossref_primary_10_1111_jce_14551
crossref_primary_10_1093_europace_euy239
crossref_primary_10_4103_ijhr_ijhr_12_21
crossref_primary_10_6061_clinics_2020_e1672
crossref_primary_10_1007_s10554_021_02493_9
crossref_primary_10_1093_europace_euz318
crossref_primary_10_1161_CIRCEP_117_005955
crossref_primary_10_1007_s15027_016_0960_5
crossref_primary_10_1016_j_hrthm_2017_07_009
Cites_doi 10.1161/CIRCULATIONAHA.115.016871
10.1016/j.jacc.2011.08.068
10.1093/eurheartj/ehn024
10.1056/NEJM199809033391003
10.1111/j.1540-8159.2004.00620.x
10.1186/s12955-014-0156-6
10.1111/jce.12529
10.1056/NEJMoa1408288
10.1093/europace/eus027
10.1111/j.1524-4733.2006.00108.x
10.1161/CIRCULATIONAHA.104.518837
10.1186/1471-2261-13-1
10.5603/CJ.a2015.0037
10.1056/NEJMoa1602014
ContentType Journal Article
Contributor Universitat de Barcelona
Contributor_xml – sequence: 1
  fullname: Universitat de Barcelona
Copyright The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.
(c) Kuck, Karl-Heinz et al., 2016 info:eu-repo/semantics/openAccess
The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. 2016
Copyright_xml – notice: The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.
– notice: (c) Kuck, Karl-Heinz et al., 2016 info:eu-repo/semantics/openAccess
– notice: The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology. 2016
CorporateAuthor FIRE AND ICE Investigators
CorporateAuthor_xml – name: FIRE AND ICE Investigators
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
XX2
5PM
DOI 10.1093/eurheartj/ehw285
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Recercat
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1522-9645
EndPage 2865
ExternalDocumentID PMC5070448
oai_recercat_cat_2072_302080
27381589
10_1093_eurheartj_ehw285
Genre Randomized Controlled Trial
Journal Article
GrantInformation_xml – fundername: ;
GroupedDBID ---
-E4
.2P
.I3
.XZ
.ZR
08P
0R~
18M
1TH
29G
2WC
4.4
482
48X
53G
5GY
5RE
5VS
5WA
5WD
70D
AABZA
AACZT
AAFWJ
AAJKP
AAJQQ
AAMVS
AAOGV
AAPNW
AAPQZ
AAPXW
AARHZ
AAUAY
AAUQX
AAVAP
AAYXX
ABDFA
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABNHQ
ABNKS
ABOCM
ABPQP
ABPTD
ABQLI
ABQNK
ABVGC
ABWST
ABXVV
ABZBJ
ACGFO
ACGFS
ACPRK
ACUFI
ACUTJ
ACUTO
ACYHN
ADBBV
ADEYI
ADEZT
ADGHP
ADGZP
ADHKW
ADHZD
ADIPN
ADNBA
ADOCK
ADQBN
ADRTK
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEWNT
AFFZL
AFIYH
AFOFC
AFXAL
AFYAG
AGINJ
AGKEF
AGORE
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AIAGR
AIJHB
AJBYB
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APWMN
ATGXG
AXUDD
BAWUL
BAYMD
BCGUY
BCRHZ
BEYMZ
BHONS
BTRTY
BVRKM
C45
CDBKE
CITATION
CS3
CZ4
DAKXR
DIK
DILTD
D~K
E3Z
EBS
EE~
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HW0
HZ~
IOX
J21
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
M-Z
M41
MHKGH
ML0
N9A
NGC
NOMLY
NOYVH
NU-
NVLIB
O9-
OAUYM
OAWHX
OB3
OCZFY
ODMLO
OGROG
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
R44
RD5
ROL
ROX
ROZ
RUSNO
RW1
RXO
SEL
TCURE
TEORI
TJX
W8F
WOQ
X7H
YAYTL
YKOAZ
YXANX
ZKX
~91
ADJQC
ADRIX
AFXEN
CGR
CUY
CVF
ECM
EIF
M49
NPM
7X8
XX2
5PM
ID FETCH-LOGICAL-c504t-4b2923a4899fb0c6769179f3e1e8a376f804d306b2b5f811a80b5584f39ceae33
ISSN 0195-668X
1522-9645
IngestDate Thu Aug 21 18:08:29 EDT 2025
Fri Aug 29 12:43:47 EDT 2025
Fri Jul 11 12:30:19 EDT 2025
Wed Feb 19 02:36:57 EST 2025
Tue Jul 01 03:20:08 EDT 2025
Thu Apr 24 23:08:52 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 38
Keywords Rehospitalization
Radiofrequency
Cryoballoon
Atrial fibrillation
Catheter ablation
Follow-up
Language English
License The Author 2016. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c504t-4b2923a4899fb0c6769179f3e1e8a376f804d306b2b5f811a80b5584f39ceae33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
OpenAccessLink https://recercat.cat/handle/2072/302080
PMID 27381589
PQID 1826711545
PQPubID 23479
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_5070448
csuc_recercat_oai_recercat_cat_2072_302080
proquest_miscellaneous_1826711545
pubmed_primary_27381589
crossref_citationtrail_10_1093_eurheartj_ehw285
crossref_primary_10_1093_eurheartj_ehw285
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-10-07
PublicationDateYYYYMMDD 2016-10-07
PublicationDate_xml – month: 10
  year: 2016
  text: 2016-10-07
  day: 07
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle European heart journal
PublicationTitleAlternate Eur Heart J
PublicationYear 2016
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Fürnkranz (2016101823583207000_37.38.2858.2) 2014; 25
2016101823583207000_37.38.2858.5
2016101823583207000_37.38.2858.4
2016101823583207000_37.38.2858.7
2016101823583207000_37.38.2858.6
2016101823583207000_37.38.2858.9
2016101823583207000_37.38.2858.8
2016101823583207000_37.38.2858.11
2016101823583207000_37.38.2858.12
2016101823583207000_37.38.2858.13
2016101823583207000_37.38.2858.1
2016101823583207000_37.38.2858.3
2016101823583207000_37.38.2858.10
Wu (2016101823583207000_37.38.2858.14) 2014; 12
27593103 - Eur Heart J. 2016 Oct 7;37(38):2866-2868
References_xml – ident: 2016101823583207000_37.38.2858.8
  doi: 10.1161/CIRCULATIONAHA.115.016871
– ident: 2016101823583207000_37.38.2858.6
  doi: 10.1016/j.jacc.2011.08.068
– ident: 2016101823583207000_37.38.2858.11
  doi: 10.1093/eurheartj/ehn024
– ident: 2016101823583207000_37.38.2858.3
  doi: 10.1056/NEJM199809033391003
– ident: 2016101823583207000_37.38.2858.9
  doi: 10.1111/j.1540-8159.2004.00620.x
– volume: 12
  start-page: e2
  year: 2014
  ident: 2016101823583207000_37.38.2858.14
  article-title: Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients
  publication-title: Health Qual Life Outcomes
  doi: 10.1186/s12955-014-0156-6
– volume: 25
  start-page: 1314
  year: 2014
  ident: 2016101823583207000_37.38.2858.2
  article-title: Rationale and Design of FIRE AND ICE: a multicenter randomized trial comparing efficacy and safety of pulmonary vein isolation using a cryoballoon versus radiofrequency ablation with 3D-reconstruction
  publication-title: J Cardiovasc Electrophysiol
  doi: 10.1111/jce.12529
– ident: 2016101823583207000_37.38.2858.5
  doi: 10.1056/NEJMoa1408288
– ident: 2016101823583207000_37.38.2858.4
  doi: 10.1093/europace/eus027
– ident: 2016101823583207000_37.38.2858.13
  doi: 10.1111/j.1524-4733.2006.00108.x
– ident: 2016101823583207000_37.38.2858.10
  doi: 10.1161/CIRCULATIONAHA.104.518837
– ident: 2016101823583207000_37.38.2858.12
  doi: 10.1186/1471-2261-13-1
– ident: 2016101823583207000_37.38.2858.7
  doi: 10.5603/CJ.a2015.0037
– ident: 2016101823583207000_37.38.2858.1
  doi: 10.1056/NEJMoa1602014
– reference: 27593103 - Eur Heart J. 2016 Oct 7;37(38):2866-2868
SSID ssj0008616
Score 2.6111436
Snippet The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs. radiofrequency...
AIMS: The primary safety and efficacy endpoints of the randomized FIRE AND ICE trial have recently demonstrated non-inferiority of cryoballoon vs....
SourceID pubmedcentral
csuc
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2858
SubjectTerms Atrial Fibrillation
Cardiac catheterization
Cateterisme cardíac
Catheter Ablation
Cryosurgery
Editor's Choice
Fast Track
Fasttrack Clinical
Fibril·lació auricular
Humans
Pulmonary Veins
Quality of Life
Radio frequency
Radiofreqüència
Recurrence
Treatment Outcome
Title Cryoballoon or radiofrequency ablation for symptomatic paroxysmal atrial fibrillation: reintervention, rehospitalization, and quality-of-life outcomes in the FIRE AND ICE trial
URI https://www.ncbi.nlm.nih.gov/pubmed/27381589
https://www.proquest.com/docview/1826711545
https://recercat.cat/handle/2072/302080
https://pubmed.ncbi.nlm.nih.gov/PMC5070448
Volume 37
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bj5NAFJ7UmhhfjHfrLWPii3axUG6Db9rs2nVTHza7Sd_IDB2yVRYaCjHtr_Kn-JM8ZwYo7FajPpS0QGcg52POHOY73yHktS-EF_iWawSxyyFAsZjBAuEZgS_BHdkWxM2YOzz74k3Pnc9zd97r_WyxlspCvIu2e_NK_seqsA_silmy_2DZplHYAd_BvrAFC8P2r2w8yTco55FkOOnLhzlfLLM41-TozZCLZMckXG8uV0Wm9VlXHLkr60uUCdBVO2Ik_idJw_TI5bLFhUQz5PKiqjBSJW7WtE-dlbkxsthIlrEcZmUBt6poXmpSe3R8eqg0rI4nh0PV297FACysXQzbd63Wl_RgfcLzxJjCNW0buOEC_8dJnn4DX7vtZOrsCAulusiT4anKAt89BjNZbKs8H8Xn5J13H5anWHTaP8tqvIZYOvC0ImU9oGsVmQq4WjumHp6Z1om_5je0ppYsc3W3X_H7xfexLibUAtLqUiEJ05ksV5c-uqLWXR-6QW6OIXDBmhqf5jvSEfOserEcuhw1HY50dyhNXTXQmSf1o3UZ7YuBrlJ5W3Ojs7vkThXU0A8aofdIT6b3ya1ZRdt4QH60gEqznHaBSmugUgAqbQGV7oBKNVBpG6jvaRemB_QaSA8oQIJegSitIUqXKQWIUoQoBYhSgChV_Twk50eHZ5OpUZUKMSLXdArDEWOIVLjDgiAWZoS8bfA0sS0tyTj40JiZzgKiYzEWbswsizNTuDD3ju0gklza9iPST7NUPiHUY_bCjETg8yhwmIxEBE5RWgubOdw0F-6AjGrDhFGlo4_lXJJQ8znssLFqqK06IG-af6y0hswfzn2Ltg5huiPziBchyr83P_AzNv1xaGNtXXNAXtWICMEr4FIfT2VWrkN8a-Cj0hY0-FgjpOm6RtiA-B3sNCdgl90j6fJCKc9D8Gg6Dnv62zafkdu75_Q56Rd5KV_ArL0QL9WD8Audevv0
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cryoballoon+or+radiofrequency+ablation+for+symptomatic+paroxysmal+atrial+fibrillation%3A+reintervention%2C+rehospitalization%2C+and+quality-of-life+outcomes+in+the+FIRE+AND+ICE+trial&rft.jtitle=European+heart+journal&rft.au=Kuck%2C+Karl-Heinz&rft.au=F%C3%BCrnkranz%2C+Alexander&rft.au=Chun%2C+K+R+Julian&rft.au=Metzner%2C+Andreas&rft.date=2016-10-07&rft.eissn=1522-9645&rft.volume=37&rft.issue=38&rft.spage=2858&rft_id=info:doi/10.1093%2Feurheartj%2Fehw285&rft_id=info%3Apmid%2F27381589&rft.externalDocID=27381589
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0195-668X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0195-668X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0195-668X&client=summon